What’s new

• Kilitch has started operations at its new nutraceutical block in Pen, Maharashtra.
• No capacity, investment, or expected revenue figures disclosed.
• The block is part of the rights issue-funded greenfield project — a known next step.

Why it matters

The block is a positive operational milestone but lacks financial detail to move the needle. With trailing revenue growth of 46%, concrete numbers are needed to gauge eventual contribution.

What we’re watching

• Any future disclosure of capacity utilisation or revenue guidance for this block.
• Early revenue contribution from this block in upcoming quarterly results.
• Updates on the broader greenfield project timeline and remaining milestones.

The full read

Kilitch Drugs has started its nutraceutical manufacturing block at the new Pen plant in Maharashtra. The filing gives no numbers: no capacity, no investment outlay, no revenue guidance. The block is a known next step in the rights issue-funded greenfield project. For a company growing trailing revenue at 46% and trading at a P/E of 20.8, this is a steady operational milestone but not a near-term catalyst. The market cap of ₹627 crore means even a fully ramped nutraceutical line would need material scale to move the needle. Quarterly disclosures will show real output. As filings go, this one signals progress without surprises.

Primary source: BSE · NSE